Eptinezumab Achieved Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial (P4.092)

Read Full-text

Listen

Save

• Abstract
• Literature Map
• Citations
• Similar Papers

Abstract

Translate Article

Explore effects of eptinezumab on migraine activity from Day 1 post iv infusion through Week 12 in patients with frequent episodic migraine.

• # Prevention Of Migraine
• # Meaningful Reductions